The Cytochrome P450 11B2 Mitochondrial pipeline drugs market research report outlays comprehensive information on the Cytochrome P450 11B2 Mitochondrial targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cytochrome P450 11B2 Mitochondrial pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Cardiovascular, Genito Urinary System, Hormonal Disorders, and Metabolic Disorders which include the indications Resistant Hypertension, Hypertension, Chronic Kidney Disease (Chronic Renal Failure), Primary Hyperaldosteronism, Pituitary ACTH Hypersecretion (Cushing Disease), and Cardiometabolic Disease. It also reviews key players involved in Cytochrome P450 11B2 Mitochondrial targeted therapeutics development with respective active and dormant or discontinued products.

The Cytochrome P450 11B2 Mitochondrial pipeline targets constitutes close to 11 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 3, 2, 1, 2, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

Cytochrome P450 11B2 Mitochondrial overview

Aldosterone synthase is a steroid hydroxylase cytochrome P450 enzyme involved in the biosynthesis of the mineralocorticoid aldosterone. It is only expressed in the zona glomerulosa of the adrenal cortex and is primarily regulated by the renin-angiotensin system. It synthesizes aldosterone in humans and plays an important role in electrolyte balance and blood pressure. Inhibition of aldosterone synthase is used as a medical treatment for hypertension, heart failure, and renal disorders.

For a complete picture of Cytochrome P450 11B2 Mitochondrial’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.